BioVie Inc.

What they do

BioVie is a clinical-stage company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Its lead asset, bezisterim (NE3107), is an investigational oral small molecule intended to inhibit inflammation-driven insulin resistance and inflammatory cascades, being tested in Alzheimer's disease, Parkinson's disease, and long COVID. The company acquired bezisterim from NeurMedix, Inc. in June 2021 and holds patents in the United States, Australia, Canada, Europe, and South Korea.

Revenue drivers

• No approved products — The company has never generated any revenues and has no products approved for commercial sale; all operations are research and development focused.
• Bezisterim (NE3107) — Investigational drug candidate for Alzheimer's, Parkinson's, and long COVID; potential revenue depends on regulatory approval and commercialization, which has not occurred.
• BIV201 — Another product candidate noted in risk factors; no commercial revenue currently, and subject to Orphan Drug exclusivity considerations.

Recent performance

For fiscal year 2026 (ended June 30, 2026), BioVie reported a net loss of $22.1 million and diluted EPS of -$3.05. Operating cash flow was -$19.0 million, consistent with fiscal 2025. As of June 30, 2026, the company had cash and equivalents of $9.0 million, total assets of $14.3 million, total liabilities of $4.0 million, and shareholder equity of $10.3 million. No revenue was reported in recent quarters, reflecting the pre-commercial stage.

Strategy

BioVie is focused on advancing bezisterim through clinical development for Alzheimer's disease, Parkinson's disease, and long COVID. The company completed a Phase 2 study of bezisterim for Parkinson's disease (NCT05083260) in December and continues to test the molecule in AD and long COVID. Management emphasizes the potential of bezisterim's unique mechanism of action—inhibiting ERK and NF-κB pathways—to differentiate it from existing treatments. The company also maintains a pipeline for advanced liver disease, though details are limited in the provided excerpts.

Risks

• No revenue and potential cessation — The company has never generated revenues and may never achieve profitability, which could cause it to cease operations.
• Clinical development uncertainty — Successful development of biopharmaceuticals is highly uncertain and dependent on numerous factors beyond the company's control, including trial results and regulatory approval.
• Third-party contractor dependence — If third-party contractors fail to perform or comply with regulatory requirements, the company may not obtain regulatory approval or commercialize its product candidates.
• Litigation exposure — The company is subject to securities class action litigation and may face similar or other litigation in the future, which could materially adversely affect its business.

Outlook

Management expects continued research and development activities, with a focus on advancing bezisterim in AD, PD, and long COVID. The company acknowledges that its capital needs are significant and may require additional financing. Forward-looking statements highlight risks related to regulatory compliance and the ability to secure necessary capital. No specific financial guidance was provided in the excerpts.